ACHV - アチ―ブ・ライフ・サイエンス （Achieve Life Sciences Inc. ） アチ―ブ・ライフ・サイエンスACHVのチャート
ACHVの企業情報
| symbol | ACHV |
|---|---|
| 会社名 | Achieve Life Science Inc （アチ―ブ・ライフ・サイエンス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: In Vitro_In Vivo Diagnostic Substances |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アチーブ・ライフ・サイエンス(Achieve Life Sciences Inc.)(旧名:OncoGenex Pharmaceuticals Inc)は癌患者の治療抵抗性に対応する治療法の開発・商業化に従事する臨床段階のバイオ医薬品会社である。同社はカナダおよび米国に事業を展開するがん治療の開発・商品化に従事する。同社は｢Custirsen｣、｢Apatorsen｣及び｢OGX-225｣の3種類の薬品候補を保有する。同社は腫瘍細胞の適応防御を無効にするために、これらの特定のタンパク質を標的にする。それによって、各種のがん治療法による攻撃を受けやすい腫瘍細胞をレンダリングする。｢Custirsen｣と｢Apatorsen｣は臨床段階の製品候補である。｢Custirsen｣は2つの第III相試験で評価される。｢Apatorsen｣は熱ショックタンパク質27（Hsp27）の産生を阻害するように設計された製品候補である。 アチ―ブ・ライフ・サイエンスは米国のバイオ医薬品メ―カ―。がん治療薬の開発と商業化を手掛ける。製品候補にはcustirsen、apatorsen、およびOGX-225があり、前立腺がん治療のCustirsen、未治療膵癌治療のapatorsenは臨床試験段階にある。本社所在地はワシントン州。 achieve life sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic. |
| 本社所在地 | 1001 W. Broadway Suite 400 Vancouver British Columbia 98011 CAN |
| 代表者氏名 | Richard Stewart リチャード・スチュワート |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 425-686-1500 |
| 設立年月日 | 33512 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 13人 |
| url | www.oncogenex.com |
| nasdaq_url | https://www.nasdaq.com/symbol/achv |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -11.66100 |
| 終値（lastsale） | 2.53 |
| 時価総額（marketcap） | 11514042.65 |
| 時価総額 | 時価総額（百万ドル） 14.76807 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -0.48293 |
| 当期純利益 | 当期純利益（百万ドル） -16.02200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Achieve Life Sciences Inc revenues was not reported. Net loss increased from $371K to $5.8M. Higher net loss reflects General_Administrative increase from $352K to $3.3M (expense) Research_Development increase from $123K to $2.1M (expense) General and administrative increase from $0K to $258K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.77 to -$4.25. |
ACHVのテクニカル分析
ACHVのニュース
Lake Street Capital Markets maintains Achieve Life Sciences at ''buy'' with a price target of $19.00 2023/05/31 13:02:38 Investing.com
https://www.investing.com/news/pro/oncogenex-pharmaceuticals-receives-investment-bank-analyst-rating-update-3095044
Achieve Life Sciences stock down on pricing $16.5M stock offering 2023/05/25 13:23:57 Seeking Alpha
Achieve Life Sciences (ACHV) shares are down 2.24% premarket on Thursday after the firm has entered into a securities purchase pact with certain institutional investors providing for…
Achieve Life Sciences Prices 3M Share Offering at $5.50/sh 2023/05/25 13:02:03 Investing.com
https://www.investing.com/news/assorted/achieve-life-sciences-prices-3m-share-offering-at-550sh-432SI-3091068
Can''t Kick the Bud? Achieve''s Cytisinicline Proves Promising in Phase 3 Smoking Cessation Trial 2023/05/23 16:46:32 Benzinga
Achieve Life Sciences Inc (NASDAQ: ACHV ) announced topline results from the second Phase 3 ORCA-3 trial of cytisinicline . Consistent with the previously reported Phase 3 ORCA-2 study, ORCA-3 showed a statistically significant benefit in helping people to quit smoking compared to placebo, with low rates of adverse events. The 6- and 12-week cytisinicline treatment durations demonstrated statistically significant smoking cessation on the primary and secondary efficacy analyses compared to placebo. Primary Endpoint: Subjects who received 12 weeks of … Full story available on Benzinga.com
BJ''s Wholesale, Kingsoft Cloud, Zoom Video And Other Big Stocks Moving Lower On Tuesday 2023/05/23 14:36:51 Benzinga
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 30 points on Tuesday. Here are some big stocks recording losses in today’s session. Microvast Holdings, Inc. (NASDAQ: MVST ) tumbled 22.3% to $1.71 after the US Energy Department reportedly cancelled contract negotiations for a $200 million award for the company. Achieve Life Sciences, Inc. (NASDAQ: ACHV ) dropped 14.7% to $6.95 as the company reported topline results from Phase 3 ORCA-3 trial of cytisinicline. Integra LifeSciences Holdings Corporation (NASDAQ: IART ) dropped 13.5% to $43.87 after the company announced it initiated a voluntary global recall … Full story available on Benzinga.com
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial 2023/03/29 12:04:03 Investing.com
https://www.investing.com/news/assorted/achieve-life-sciences-announces-last-subject-last-visit-completed-in-phase-3-orca3-trial-432SI-3043853
Achieve Life Sciences, Inc. (ACHV) Q4 2022 Earnings Call Transcript 2023/03/17 01:33:05 Seeking Alpha
Achieve Life Sciences, Inc. (NASDAQ:NASDAQ:ACHV) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ETCompany ParticipantsNicole Jones - Investor RelationsJohn Bencich - Chief…
Achieve Life Sciences GAAP EPS of -$0.83 beats by $0.06 2023/03/16 20:18:35 Seeking Alpha
Achieve Life Sciences press release (ACHV): Q4 GAAP EPS of -$0.83 beats by $0.06.As of December 31, 2022, the company’s cash, cash equivalents, and restricted cash was…
Achieve Life Sciences Q4 2022 Earnings Preview 2023/03/15 21:35:43 Seeking Alpha
Achieve Life Sciences (ACHV) is scheduled to announce Q4 earnings results on Thursday, March 16th, after market close.The consensus EPS Estimate is -$0.95 and the consensus Revenue…
Achieve Life Sciences''s Earnings: A Preview 2023/03/15 16:01:37 Benzinga
Achieve Life Sciences (NASDAQ: ACHV ) is set to give its latest quarterly earnings report on Thursday, 2023-03-16. Here''s what investors need to know before the announcement. Analysts estimate that Achieve Life Sciences will report an earnings per share (EPS) of $-0.83. Achieve Life Sciences bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug 2022/04/04 17:38:57 Seeking Alpha
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2021 Results - Earnings Call Transcript 2022/03/10 23:04:08 Seeking Alpha
Achieve Life Sciences GAAP EPS of -$0.76 misses by $0.07 2022/03/10 14:29:13 Seeking Alpha
Achieve Life Sciences press release (ACHV): Q4 GAAP EPS of -$0.76 misses by $0.07.As of December 31, 2021, the company’s cash, cash equivalents, and restricted cash was $43.1 million.